Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naltrexone (oral) Clear all
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

Employment-Based Depot Naltrexone Clinical Trial II

NCT00684775
View directory record Official record
Conditions
Opiate Dependence
Interventions
Work Plus Naltrexone Contingency
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 7, 2026, 6:10 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

NCT05940324
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine, Naltrexone Pill, Placebo pill
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone

NCT02294253
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

Medication and Counseling for Controlled Drinking (Project SMART)

NCT00444418
View directory record Official record
Conditions
Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Interventions
Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy
Drug · Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 7, 2026, 6:10 PM EDT
Withdrawn Phase 2 Interventional

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

NCT04115020
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

NCT01721070
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 2 Interventional

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704
View directory record Official record
Conditions
Covid19, Long COVID-19, Post-COVID-19 Syndrome
Interventions
Naltrexone, NAD+
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

Targeted Interventions for Weight-Concerned Smokers

NCT00105482
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Naltrexone, Transdermal nicotine replacement, Behavioral counseling
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 7, 2026, 6:10 PM EDT
Not yet recruiting Phase 2 Interventional

Low-Dose Naltrexone For ME/CFS: Dose-Finding

NCT07285473
View directory record Official record
Conditions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions
Low-Dose Naltrexone, 1.5mg, Low-Dose Naltrexone, 3.0mg, Low-Dose Naltrexone, 4.5mg, Low-Dose Naltrexone, 6.0mg
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT03766893
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

NCT01967381
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Methamphetamine (Desoxyn®)
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 4 Interventional

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

NCT04219540
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B (SUBLOCADETM), XR-NTX
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 7, 2026, 6:10 PM EDT
Completed No phase listed Observational

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

NCT03718104
View directory record Official record
Conditions
Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions
Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis
Other · Genetic
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 7, 2026, 6:10 PM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Targeted Naltrexone to Support Individuals Participating in Dry January

NCT07132177
View directory record Official record
Conditions
Alcohol Misuse
Interventions
Naltrexone (oral tablets)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 7, 2026, 6:10 PM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

Memantine and Naltrexone Treatment for Opioid Dependence

NCT00125515
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 7, 2026, 6:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

NCT02089295
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 7, 2026, 6:10 PM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 7, 2026, 6:10 PM EDT